HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 167 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2016. The put-call ratio across all filers is 0.15 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $609,000 | -3.8% | 14,265 | -39.6% | 0.05% | -24.6% |
| Q2 2020 | $633,000 | -83.9% | 23,622 | -89.3% | 0.06% | -45.4% |
| Q4 2019 | $3,928,000 | +1529.9% | 221,558 | +1565.8% | 0.12% | +1387.5% |
| Q3 2018 | $241,000 | -74.5% | 13,300 | -72.5% | 0.01% | -50.0% |
| Q1 2018 | $946,000 | -66.2% | 48,300 | -65.0% | 0.02% | -61.0% |
| Q4 2017 | $2,797,000 | +732.4% | 138,100 | +305.0% | 0.04% | +412.5% |
| Q4 2016 | $336,000 | +1.2% | 34,100 | +24.0% | 0.01% | -27.3% |
| Q3 2016 | $332,000 | -34.4% | 27,500 | -53.2% | 0.01% | -54.2% |
| Q2 2016 | $506,000 | -10.0% | 58,700 | -1.2% | 0.02% | -11.1% |
| Q1 2016 | $562,000 | +15.2% | 59,400 | +63.2% | 0.03% | -27.0% |
| Q3 2015 | $488,000 | +82.1% | 36,400 | +93.6% | 0.04% | +42.3% |
| Q1 2015 | $268,000 | +49.7% | 18,800 | +1.1% | 0.03% | -7.1% |
| Q4 2014 | $179,000 | – | 18,600 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,816,162 | $195,784,000 | 9.33% |
| BB BIOTECH AG | 5,846,564 | $57,764,000 | 2.74% |
| QVT Financial LP | 4,556,090 | $45,014,000 | 2.44% |
| Parametrica Management Ltd | 29,578 | $292,000 | 2.21% |
| SECTORAL ASSET MANAGEMENT INC | 4,389,682 | $43,370,000 | 1.84% |
| Belmont Global Advisors, Inc. | 257,000 | $2,539,000 | 1.83% |
| HARVEY CAPITAL MANAGEMENT INC | 394,550 | $3,898,000 | 1.40% |
| Lombard Odier Asset Management (USA) Corp | 1,350,000 | $13,338,000 | 0.70% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 6,199,685 | $61,253,000 | 0.63% |
| Callan Capital, LLC | 199,230 | $1,968,000 | 0.53% |